. 2012 Mar 9;8:105–130. doi: 10.2147/TCRM.S29830

Table I.

Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (boceprevir provided at a dose of 800 mg three times per day during weeks 4–48 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks) among patients with compensated cirrhosis

Trial	Intervention		Control		Relative risk (95% CI)

	N	Pooled (95% CI)	N	Pooled (95% CI)
Sustained virologic response
Naïve patients
Kwo et al6	3/6	44% (27%–61%)	2/8	39% (20%–59%)	1.07 (0.55–2.09)
Poordad et al5	10/24	44% (27%–61%)	6/13	39% (20%–59%)	1.07 (0.55–2.09)
Experienced patients
Bacon et al11	17/22	63% (37%–86%)	0/10	5% (0.1%–7%)	6.91 (1.46–32.61)
Flamm et al12	12/24	63% (37%–86%)	1/9	5% (0.1%–7%)	6.91 (1.46–32.61)

Abbreviation: CI, confidence interval.